Peginterferon alfa-2b
Also known as: IFN‑α2b‑PEG, PEG-IFN alfa-2b, PEG‑IFN alfa‑2b, Pegasys, PegIntron, Pegylated interferon alfa-2b, SCH 54031, Sylatron
Source Peginterferon alfa-2b at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peginterferon alfa‑2b is a pegylated form of interferon‑alpha used by prescription for chronic hepatitis C infection. The polyethylene glycol (PEG) moiety prolongs the drug’s circulating half‑life, allowing subcutaneous injection once weekly instead of more frequent dosing required for non‑pegylated interferon. It is typically administered in combination with ribavirin to enhance antiviral efficacy.
Mechanism of Action
Peginterferon alfa‑2b binds to interferon‑alpha receptors on hepatocytes and immune cells, activating the JAK‑STAT signaling cascade. This leads to transcription of interferon‑stimulated genes that inhibit viral replication, enhance antigen presentation, and modulate immune responses. The attached 12 kDa PEG chain increases molecular size, slowing absorption, reducing renal clearance, and extending systemic exposure, thereby sustaining antiviral signaling over a longer interval.
What the Research Shows
Review articles describe pegylation as a strategy that markedly lengthens the absorption half‑life of interferon alfa (from ~2 h for native interferon to ~4.6 h for peginterferon alfa‑2b) and reduces clearance to about one‑tenth of the unmodified molecule. Pharmacokinetic studies note a modestly lower volume of distribution compared with conventional interferon. Clinical commentary reports that pegylated interferons achieve higher sustained viral load reductions than non‑pegylated forms, especially when paired with ribavirin, and that tolerability is comparable. Direct comparative trials between peginterferon alfa‑2b and the related peginterferon alfa‑2a have not been published.
Reported Benefits
Pegylation enables once‑weekly subcutaneous dosing, improving patient convenience relative to daily injections of standard interferon. The extended half‑life maintains antiviral activity longer, resulting in greater reductions in hepatitis C viral load and higher rates of sustained virological response when combined with ribavirin. Reported tolerability is similar to that of non‑pegylated interferon, suggesting no major increase in adverse effects.
Limitations of the Evidence
Evidence is limited to chronic hepatitis C; the drug is not curative and its long‑term impact on outcomes such as cirrhosis or liver cancer remains inferential. No head‑to‑head trials have compared peginterferon alfa‑2b with the alternative pegylated product (alfa‑2a), leaving uncertainty about any clinical advantage of the pharmacokinetic differences. Data on efficacy in other viral infections or disease states are absent from the cited literature.
Safety Considerations
Safety data indicate that peginterferon alfa‑2b is tolerated similarly to conventional interferon alfa, with the usual interferon‑related adverse effects expected (flu‑like symptoms, hematologic changes, and hepatic enzyme elevations). Because the pegylated formulation does not markedly alter the side‑effect profile, clinicians monitor patients for these known reactions and adjust therapy as needed. No new safety signals specific to the PEG moiety are reported in the abstracts.
How It Is Administered
Peginterferon alfa‑2b is supplied for subcutaneous injection, typically administered once weekly due to its prolonged half‑life. The formulation contains a linear 12 kDa polyethylene glycol chain that slows absorption and reduces renal clearance, allowing sustained drug levels between doses.
Routes of Administration
Goals & Uses
- Chronic Hepatitis C treatmentAntiviralHigh
- Malignant melanomaOncologyHigh
- Antiproliferative effect in hematologic malignanciesOncologyModerate
- Adjuvant melanoma therapyOncologyHigh
- Antiviral ImmunomodulationImmunologyModerate
- Chronic hepatitis C genotype 1AntiviralModerate
- Renal cell carcinomaOncologyHigh
Contraindications
- Severe psychiatric disorders (uncontrolled)PsychiatryHigh
- Hypersensitivity to interferon alfa or PEGImmunologicHigh
- Decompensated liver disease (Child-Pugh B/C)HepaticHigh
- Severe psychiatric disorderPsychiatricHigh
- Autoimmune disease (e.g., SLE, MS)AutoimmuneHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Neonates and Infants (benzyl alcohol-containing formulations)PediatricHigh
- Autoimmune hepatitisHepatic / AutoimmuneHigh
Adverse Effects
- Neuropsychiatric effects (depression, irritability, suicidal ideation)PsychiatricCommon
- Injection site reactionsLocalCommon
- Flu‑like syndromeSystemicCommon
- NeutropeniaHematologicUncommonLow neutrophil count
- Flu-like symptoms (fever, chills, myalgia, fatigue)Systemic / ConstitutionalCommon
- Myelosuppression (neutropenia, thrombocytopenia, anemia)HematologicCommon
- DepressionPsychiatricCommon
- Retinopathy and optic neuropathyOphthalmologicRare
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Injection‑site reactionLocalCommon
- Thyroid dysfunction (hypo- or hyperthyroidism)EndocrineUncommon
Drug Interactions
- Myelosuppressive agents (e.g., azathioprine, chemotherapy)High
- Immunosuppressants (e.g., cyclosporine)Moderate
- RibavirinModerate
- CorticosteroidsLow
- MethadoneModerate
- Theophylline / CYP1A2 substratesModerate
Population Constraints
- Psychiatric historyNeuropsychiatricRelative
- PregnancyReproductive SafetyAbsolute
- Pediatric patients (<18 y)AgeRelative
- Elderly (>75 y)AgeRelative
- Renal impairment (CrCl <50 mL/min)RenalRelative
- Renal impairment (CrCl <30 mL/min)RenalRelative
- Elderly (≥65 years)GeriatricRelative
- Pediatric patients (<3 years)PediatricAbsolute
Regulatory Status
- European UnionApprovedApproved: malignant melanoma, renal cell carcinomaSame indications as US.
- United StatesApprovedApproved: malignant melanoma, renal cell carcinomaHepatitis C indication withdrawn in 2014.
- United KingdomApprovedApproved: malignant melanoma, renal cell carcinomaRegulated under NHS formularies.
Approved in the US for melanoma and renal cell carcinoma; hepatitis C indication withdrawn after newer direct‑acting antivirals became standard of care.
Evidence & Sources
- Journal ArticleModerateBayés M, Rabasseda X, Prous JR2003-01-01T00:00:00.000000Z
- Journal ArticleModerateBaker DE2001-01-01T00:00:00.000000Z
- Journal ArticleModerateBayes M, Rabasseda X, Prous JR2002-01-01T00:00:00.000000Z
- Journal ArticleModerateZeuzem S, Welsch C, Herrmann E2003-01-01T00:00:00.000000Z
- Journal ArticleModerateBayes M, Rabasseda X, Prous JR2006-01-01T00:00:00.000000Z
Frequently Asked Questions
Why is peginterferon given only once a week?
The attached polyethylene glycol increases the molecule’s size, slowing its absorption and reducing clearance. This prolongs systemic exposure, so antiviral activity is maintained for several days, permitting weekly dosing instead of daily injections required for non‑pegylated interferon.
Is peginterferon alfa‑2b more effective than regular interferon?
Clinical commentary notes that pegylated interferons achieve better viral load reductions than non‑pegylated forms, particularly when combined with ribavirin. However, direct comparative trials are limited, and the improvement is attributed mainly to the longer exposure rather than a different mechanism.
Can peginterferon alfa‑2b be used without ribavirin?
While peginterferon can be given as monotherapy, the literature emphasizes that combination with ribavirin is more effective for chronic hepatitis C. Monotherapy alone produces a modest response, and current practice favors the combination regimen.
Are there any unique side effects from the PEG component?
The abstracts report that tolerability of pegylated interferons is comparable to that of conventional interferon, suggesting the PEG moiety does not introduce new adverse effects. Monitoring focuses on the known interferon‑related reactions.
Has peginterferon alfa‑2b been compared head‑to‑head with peginterferon alfa‑2a?
No direct comparative studies between the two pegylated products are cited. While pharmacokinetic differences are described, it remains unknown whether these translate into distinct clinical outcomes.
What is Peginterferon alfa-2b?
Peginterferon alfa‑2b is a pegylated form of interferon‑alpha used by prescription for chronic hepatitis C infection. The polyethylene glycol (PEG) moiety prolongs the drug’s circulating half‑life, allowing subcutaneous injection once weekly instead of more frequent dosing required for non‑pegylated interferon. It is typically administered in combination with ribavirin to enhance antiviral efficacy.
What is Peginterferon alfa-2b used for?
Peginterferon alfa-2b is educationally associated with: Chronic Hepatitis C treatment, Malignant melanoma, Antiproliferative effect in hematologic malignancies, Adjuvant melanoma therapy, Antiviral Immunomodulation, Chronic hepatitis C genotype 1, Renal cell carcinoma. Educational only — not medical advice.
How is Peginterferon alfa-2b administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Peginterferon alfa-2b?
Reported adverse effects include: Neuropsychiatric effects (depression, irritability, suicidal ideation), Injection site reactions, Flu‑like syndrome, Neutropenia, Flu-like symptoms (fever, chills, myalgia, fatigue), Myelosuppression (neutropenia, thrombocytopenia, anemia), Depression, Retinopathy and optic neuropathy, Elevated liver enzymes, Injection‑site reaction, Thyroid dysfunction (hypo- or hyperthyroidism). This list is not exhaustive — consult a qualified clinician.
Who should avoid Peginterferon alfa-2b?
Recorded contraindications: Severe psychiatric disorders (uncontrolled), Hypersensitivity to interferon alfa or PEG, Decompensated liver disease (Child-Pugh B/C), Severe psychiatric disorder, Autoimmune disease (e.g., SLE, MS), Pregnancy, Neonates and Infants (benzyl alcohol-containing formulations), Autoimmune hepatitis. Consult a qualified clinician before use.